Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Regulus Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RGLS
Nasdaq
8731
https://www.regulusrx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Regulus Therapeutics Inc
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
- Mar 23rd, 2024 9:33 am
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
- Mar 21st, 2024 8:05 pm
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
- Mar 14th, 2024 4:07 pm
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
- Mar 13th, 2024 4:09 pm
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
- Mar 12th, 2024 10:32 am
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Mar 12th, 2024 10:30 am
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Jan 2nd, 2024 9:05 pm
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
- Nov 22nd, 2023 1:00 pm
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
- Nov 9th, 2023 9:05 pm
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Nov 2nd, 2023 12:00 pm
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Oct 19th, 2023 12:00 pm
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Sep 20th, 2023 11:00 am
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Sep 13th, 2023 12:00 pm
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
- Sep 5th, 2023 12:00 pm
Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?
- Aug 24th, 2023 11:33 pm
Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
- Aug 23rd, 2023 5:04 pm
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
- Aug 23rd, 2023 12:00 pm
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
- Aug 8th, 2023 8:05 pm
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
- Aug 2nd, 2023 12:00 pm
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
- Jul 18th, 2023 12:00 pm
Scroll